NetworkNewsBreaks – Healthtech Solutions Inc.’
Post# of 26
(Total Views: 170)
Posted On: 05/14/2021 3:43:13 PM
NetworkNewsBreaks – Healthtech Solutions Inc.’s (HLTT) Latest Acquisition Brings in Innovative Team of Experts
Healthtech Solutions (OTC: HLTT), focused on acquiring and investing in strategic cutting-edge health care technological opportunities, is among biotech players that have pivoted to a new model wherein multiple portfolio companies operate under one parent organization. Healthtech’s latest acquisition, Varian Biopharmaceuticals, brings to three the number of subsidiaries under its umbrella. “The acquisition of Varian by Healthtech plays to the strengths of the new portfolio model not only in drug pipeline but also by bringing in experts in an area that could attract additional investment,” reads a recent article. A precision oncology company, Varian specializes in developing atypical protein kinase C iota (“aPKCi”) inhibitors for different tumor types. Its two lead candidates are being prepared for clinical trials. The article quotes Healthtech CEO and Chairman David Rubin as saying, “The fact that [Varian Bio is] developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Healthtech Solutions (OTC: HLTT), focused on acquiring and investing in strategic cutting-edge health care technological opportunities, is among biotech players that have pivoted to a new model wherein multiple portfolio companies operate under one parent organization. Healthtech’s latest acquisition, Varian Biopharmaceuticals, brings to three the number of subsidiaries under its umbrella. “The acquisition of Varian by Healthtech plays to the strengths of the new portfolio model not only in drug pipeline but also by bringing in experts in an area that could attract additional investment,” reads a recent article. A precision oncology company, Varian specializes in developing atypical protein kinase C iota (“aPKCi”) inhibitors for different tumor types. Its two lead candidates are being prepared for clinical trials. The article quotes Healthtech CEO and Chairman David Rubin as saying, “The fact that [Varian Bio is] developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)